ClinicalTrials.gg
TerminatedNCT04078854Updated Sep 11, 2023

The Impact of Sexual Health and Amputation Focused Education on Regulation of Glucose and Amputation Prevention

An interventional study of Diabetes education in Diabetic Ulcers on Both Feet, Amputation; Traumatic, Limb and Sexual Dysfunction, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Prevention

Why this study was terminated
IRB approval expired on 3/16/2022. Study would need to be reapproved by the IRB with a new submission given the duration of expiration.
Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the effect of two types of education on HbA1c level and future amputations in inpatient diabetics after initial minor foot amputation

Read the detailed description

This is a single center prospective randomized study evaluating inpatient diabetics after initial minor foot amputations.

b) When a potential enrollee has been identified, while still inpatient, one research associate from a group of trained residents and medical students will spend 15-30 minutes with the patient to enroll and give one of the two education video presentations. The video presentations are the narrated versions of the slides attached to the IRB application. We will have both English and Spanish videos available. Because we are using video education, the education provided will be standardized across all patients, and there will be minimal variation in education provided despite using different research associates. The patients will be randomized to one of the two presentations. Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes. Each enrollee will also be asked if they are receiving structured diabetes education at the Montefiore Diabetic Center and will be encouraged to follow up to receive structured education there.

The education presentation will occur after post-operative day 1 after minor foot amputations.

Primary Outcome: HbA1c level Secondary Outcomes: LDL level, Mortality, Re-amputation (higher level or contralateral leg)

02

Conditions studied

  • Diabetic Ulcers on Both Feet
  • Amputation; Traumatic, Limb
  • Sexual Dysfunction
  • Diabetic Foot Ulcer Ischemic

Keywords

  • Diabetic Foot
  • Sexual Dysfunction
  • Amputation
03

In context

Sexual Dysfunction, Physiological

385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.

This study's enrollment of 21 is below the median of 72 across 263 interventional studies indexed under Sexual Dysfunction, Physiological.

Browse Sexual Dysfunction, Physiological studies →

Lead sponsor

Montefiore Medical Center is the lead sponsor of 416 studies on the registry; 69 are open to participants now.

Of its 87 completed or terminated interventional studies of FDA-regulated products, 76 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 6.5 and above
  • had minor foot amputation this hospitalization
  • Age 18 years old and older
  • All ethnicities
  • Both genders

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Foot amputation, sexual health

    Group 1, Experimental arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations plus sexual health

    Behavioral: Diabetes education

  • Active comparator
    Foot amputation, no sexual health

    Group 2, Control arm: inpatient diabetics after initial minor foot amputation, who will be shown video on diabetes and foot amputations, with no mention about sexual health

    Behavioral: Diabetes education

Interventions

  • BehavioralDiabetes education

    Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.

    Also known as: Sexual dysfunction in diabetes

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin A1c (HbA1c) levels

    HbA1c measures the amount of blood sugar (glucose) attached to hemoglobin

    Time frame: 3 months, 6 months, 1 year, 2 years

Secondary outcomes

  1. Change in LDL Cholesterol levels

    LDL

    Time frame: 3 months, 6 months, 1 year, 2 years

  2. Number of Deaths

    Mortality

    Time frame: 3 months, 6 months, 1 year, 2 years

  3. Number of amputations of lower extremities

    Amputation

    Time frame: 3 months, 6 months, 1 year, 2 years

  4. Number of re-amputations

    higher level or contralateral leg

    Time frame: 3 months, 6 months, 1 year, 2 years

  5. Number of patients with mobility problems

    Number of blocks patient can walk before claudication

    Time frame: 3 months, 6 months, 1 year, 2 years

07

Study locations

1 site
  • Montefiore Medical Center
    Bronx, New York 10467, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Mar 2022, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2019
First posted
Sep 6, 2019
StartActual
Jul 8, 2020
Primary completionActual
Mar 16, 2022
CompletionActual
Mar 16, 2022
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04078854
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Jul 8, 2020
Primary completion
Mar 16, 2022
Completion
Mar 16, 2022
Last update
Sep 11, 2023

Study contacts

Issam Koleilat, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion